SYMPOSIUM

Philasande Madosi
Community-based harm reduction services: Mpumalanga
[27 March 2024] | Phase 2023b [July – December 2023]
Needle & syringe reach, by gender

- **Male**: 96% reach, 686 individuals
- **Female**: 6% reach
- **Trans**: 0% reach
- **Total reach**: 96%

**Ehlanzeni**
Needle & syringe distribution & return

Ehlanzeni

- Distributed
- Returned
- Return rate

97%
HIV testing & treatment cascade

- Tested: 363
- Newly diagnosed HIV+ve: 68
- On ART: 56
- Viral load done: 29

- % HIV positive: 19%

Ehlanzeni
TB testing & treatment cascade

Ehlanzeni

- Symptom screen: 363
- Symptomatic: 2
- Diagnosed: 2
- Started Rx: 2
- Completed Rx: 2
HCV testing & treatment cascade

- HCV screen: 475
- anti-HCV +ve: 341, 72%
- Confirmed infection: 19
- Started Rx: 0
- SVR12: 0
- anti-HCV %: 0%

Ehlanezi

SACENDU
SOUTH AFRICAN COMMUNITY EPIDEMIOLOGY NETWORK ON DRUG USE

Treatment Demand Data • Service Quality Measures (SQM) • Community-Based Harm Reduction Services

saMRC
advancing life
HBV testing

HBsAg+ve %
Human rights violations

- Confiscation / destruction of injecting equipment
- Confiscation / destruction of injecting equipment and assaulted
- Confiscation / destruction of injecting equipment and arrested
- Confiscation / destruction of injecting equipment and personal photos taken without consent
- Confiscation / destruction of injecting equipment and medication taken
- Assaulted
- Falsely arrested
- Other

Total number of violations reported
Opioid substitution therapy

Ehlanzeni

- On OST (start of period): 145
- Re/Started OST: 63
- Exited/dropped out: 5
- Died: 2
- On OST (end of period): 201
Mortality

Ehlanzeni

All cause deaths
Fatal overdose

4
0
Issues, challenges & issues to note

• Direct acting antivirals for HCV treatment not yet available
Successes

- Multipurpose centre after care program for clients on OST, supported by Schoemansdal community and Traditional Council.
- 42 Clients employed and no longer using drugs
Acknowledgements